Official FDA resource
FDA concerns with unapproved GLP-1 drugs
FDA explains approval, compounding, salt-form, dosing, and fraudulent-product concerns for unapproved semaglutide and tirzepatide products.
Open official resourceThis page offers a neutral framework for finding official public information and preparing questions for a licensed healthcare professional. It does not determine whether a provider, product, or service is lawful, approved, safe, effective, or appropriate.
This resource is for general information only. It is not medical advice, legal advice, a diagnosis, a treatment recommendation, a safety evaluation, or an endorsement. Regulations and public records can change and may differ by jurisdiction. Consult an appropriately licensed professional for advice about your own circumstances and verify current requirements with the relevant public authority.
Primary resources
These links go directly to official FDA materials used for the catalog's regulatory context. State professional and pharmacy licenses still need jurisdiction-specific verification.
Official FDA resource
FDA explains approval, compounding, salt-form, dosing, and fraudulent-product concerns for unapproved semaglutide and tirzepatide products.
Open official resourceOfficial FDA registry
The FDA table identifies registered 503B outsourcing facilities. Registration does not mean the facility or its drugs are FDA-approved.
Open official resourceOfficial FDA safety resource
FDA summarizes safety concerns for certain bulk peptide substances. The page is regulatory context, not individualized medical advice.
Open official resourceApproval, authorization, registration, clearance, licensing, and compliance are different concepts. A statement about one should not be treated as proof of another. The meaning can also depend on the exact product, service, entity, and jurisdiction.
Provider wording, certificates, and marketing language are not substitutes for an official public record. Likewise, the presence of a public record does not by itself establish the quality, safety, effectiveness, or suitability of a specific offering.
When a status matters to a decision, identify the precise claim, find the relevant primary source, check its date and scope, and ask a licensed professional or appropriate public authority to explain what it means.
These prompts are conversation starters, not instructions or a substitute for individualized care.
Verification is a source-checking process, not a safety conclusion. Use the steps to test whether a public statement is supported by a relevant, current source.
Match the public business name, address, and stated role to the entity shown in an appropriate official record. Similar names can refer to different organizations.
Open the original public material when a source is available. A directory summary can omit context and may no longer reflect a changed page.
Confirm when the information was issued or last updated and which product, service, location, or entity the record actually covers.
If an official record is unavailable, ambiguous, or inconsistent, treat the point as unresolved. Do not use a missing record alone to draw a conclusion.
Transparent public information can support better questions, but it cannot establish a safety conclusion. Treat each signal as one piece of context and confirm material claims at their primary source.
Look for a consistent legal or business identity and a clear way to contact the entity.
Distinguish the provider, prescriber, pharmacy, laboratory, and other roles instead of assuming they are the same entity.
Read stated pricing, subscription, cancellation, privacy, and shipping terms in their full context.
Note what a document claims to cover, who issued it, and when. Its presence alone is not an endorsement or validation.